HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma

High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00144092

Enrollment

Registered

2005-09-05

Start date

2001-05-31

Completion date

2010-06-30

Last updated

2011-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Grade Lymphoma

Keywords

autologous and allogeneic stem cell transplantation, low grade lymphoma, mantle cell

Brief summary

Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation.

Detailed description

Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation if they have an HLA matched sibling, or an autologous transplant if they do not.

Interventions

PROCEDUREstem cell source

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* indolent histology lymphomas after relapse 1 or 2 LVEF \> 50% Creatinine \< 150 umol/L bilirubin \< 30 umol/L wbc \>3.5X10\^9/L platelets \>100X10\^9/L other medical condition as controlled

Exclusion criteria

* pregnant lactating HIV positive CNS involvement by lymphoma other malignancy

Design outcomes

Primary

Measure	Time frame
feasibility	—
mortality	—
overall survival	—
event free survival	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026